CleanCap Reagent AU is specifically designed for co-transcriptional capping, with the structure m7G(5')ppp(5')(2'OMeA)pU, to produce mRNA with a natural Cap1 structure[1]. CleanCap Reagent AU is specifically designed for self-replicating RNA based on the genomes of positive-strand RNA viruses (such as Venezuelan equine encephalitis virus (VEEV), Semliki Forest virus (SFV), and Sindbis virus (SIN)), whose positive-strand genomes begin with 5'-AU...[2, 3]. Compared to Cap0 mRNA prepared by traditional co-transcriptional capping methods (such as anti-reverse cap analog, ARCA), mRNA with a Cap1 structure exhibits superior activity, stability, and lower immunogenicity in vivo[4]. CleanCap Reagent AU can be used in conjunction with GlpBio's series of modified NTP products.
References:
[1] Henderson J M, Ujita A, Hill E, et al. Cap 1 messenger RNA synthesis with co‐transcriptional cleancap® analog by in vitro transcription[J]. Current protocols, 2021, 1(2): e39.
[2] Lu X, Wu Y, Zhao C, et al. Co‐expression of HSV‐1 ICP34. 5 enhances the expression of gene delivered by self‐amplifying RNA and mitigates its immunogenicity[J]. FEBS Open Bio, 2025.
[3] Kairuz D, Samudh N, Ely A, et al. Production, characterization, and assessment of permanently cationic and ionizable lipid nanoparticles for use in the delivery of self-amplifying RNA vaccines[J]. Pharmaceutics, 2023, 15(4): 1173.
[4] Zhang H, Ma J, Ma T, et al. GPT-driven generation and biological activity evaluation of novel mRNA trinucleotide Cap1 analogs for mRNA vaccine or immunotherapy[J]. Journal of Materials Chemistry B, 2025.